Bispecific Antibodies in Myeloma: How They Work, Side Effects & CAR-T Comparison | Peter Forsberg MD

Dr. Peter Forsberg explains how bispecific T-cell engager antibodies work for multiple myeloma, how they compare to CAR-T cell therapy, and the growing evidence that they're effective enough to move earlier in treatment, even into newly diagnosed patients. He covers the three approved BCMA-targeted bispecifics, teclistamab, elranatamab, and linvoseltamab, and talquetamab, the approved bispecific that targets GPRC5D instead, including the clinical trial data behind each, what cytokine release syndrome (CRS) actually is and how it's managed, and why IVIG antibody replacement has become a core part of bispecific treatment to help prevent serious infections. He closes with what's coming next: trispecific antibodies that target two things on the myeloma cell at once, a bispecific called cevostamab that targets a different protein called FcRH5, and ongoing work to make these treatments accessible closer to home instead of only at major cancer centers.